Page 82 - GALENIKA MEDICAL JOURNAL

43. Konigsbrugge O, Ay C. Atrial fibrillation in patients with end-stage renal 56. Hohnloser SH, Hijazi Z, Thomas L, Alexander JH, Amerena J, Hanna M,
disease on hemodialysis: Magnitude of the problem and new approach et al. Efficacy of apixaban when compared with warfarin in relation
to oral anticoagulation. Res Pract Thromb Haemost. 2019;3(4):578-88. to renal function in patients with atrial fibrillation: insights from the
ARISTOTLE trial. Eur Heart J. 2012;33(22):2821-30.
44. De Vriese AS, Heine G. Anticoagulation management in haemodialysis
patients with atrial fibrillation: evidence and opinion. Nephrol Dial 57. Mavrakanas TA, Samer CF, Nessim SJ, Frisch G, Lipman ML. Apixaban
Transplant. 2022;37(11):2072-9. Pharmacokinetics at Steady State in Hemodialysis Patients. J Am Soc
Nephrol. 2017;28(7):2241-8.
45. Huisman MV, Lip GY, Diener HC, Brueckmann M, van Ryn J, Clemens
A. Dabigatran etexilate for stroke prevention in patients with atrial 58. De Vriese AS, Caluwe R, Van Der Meersch H, De Boeck K, De Bacquer
fibrillation: resolving uncertainties in routine practice. Thromb D. Safety and Efficacy of Vitamin K Antagonists versus Rivaroxaban in
Haemost. 2012;107(5):838-47. Hemodialysis Patients with Atrial Fibrillation: A Multicenter Randomized
Controlled Trial. J Am Soc Nephrol. 2021;32(6):1474-83.
46. Van Ryn J, Goss A, Hauel N, Wienen W, Priepke H, Nar H, et al. The
discovery of dabigatran etexilate. Front Pharmacol. 2013;4:12. 59. Chen C, Cao Y, Zheng Y, Dong Y, Ma J, Zhu W, et al. Effect of Rivaroxaban
or Apixaban in Atrial Fibrillation Patients with Stage 4-5 Chronic Kidney
47. Steffel J, Collins R, Antz M, Cornu P, Desteghe L, Haeusler KG, et al. Disease or on Dialysis. Cardiovasc Drugs Ther. 2021;35(2):273-81.
2021 European Heart Rhythm Association Practical Guide on the Use
of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial 60. Grandone E, Aucella F, Barcellona D, Brunori G, Forneris G,
Fibrillation. Europace. 2021;23(10):1612-76. Gresele P, et al. Position paper on the safety/efficacy profile of
direct oral anticoagulants in patients with chronic kidney disease.
48. Yao X, Tangri N, Gersh BJ, Sangaralingham LR, Shah ND, Nath KA, et al. Consensus document from the SIN, FCSA and SISET. Blood Transfus.
Renal Outcomes in Anticoagulated Patients With Atrial Fibrillation. J Am 2020;18(6):478-85.
Coll Cardiol. 2017;70(21):2621-32.
61. Hijazi Z, Hohnloser SH, Oldgren J, Andersson U, Connolly SJ, Eikelboom
49. Yao X, Inselman JW, Ross JS, Izem R, Graham DJ, Martin DB, et al. JW, et al. Efficacy and safety of dabigatran compared with warfarin in
Comparative Effectiveness and Safety of Oral Anticoagulants Across relation to baseline renal function in patients with atrial fibrillation: a
Kidney Function in Patients With Atrial Fibrillation. Circ Cardiovasc Qual RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy)
Outcomes. 2020;13(10):e006515. trial analysis. Circulation. 2014;129(9):961-70.
50. Kreutz R, Deray G, Floege J, Gwechenberger M, Hahn K, Luft AR, et 62. Chan KE, Edelman ER, Wenger JB, Thadhani RI, Maddux FW. Dabigatran
al. Rationale and design of XARENO: XA inhibition in RENal patients and rivaroxaban use in atrial fibrillation patients on hemodialysis.
with non-valvular atrial fibrillation. Observational registry. Kardiol Pol. Circulation. 2015;131(11):972-9.
2021;79(11):1265-7.
63. Lin Y, Chao TF, Tsai ML, Tseng CJ, Wang TH, Chang CH, et al.
51. Li J, Wang L, Hu J, Xu G. Warfarin use and the risks of stroke and Cardiovascular and renal outcomes in patients with atrial
bleeding in hemodialysis patients with atrial fibrillation: A systematic fibrillation and stage 4-5 chronic kidney disease receiving direct oral
review and a meta-analysis. Nutr Metab Cardiovasc Dis. 2015;25(8):706- anticoagulants: a multicenter retrospective cohort study. J Thromb
13. Thrombolysis. 2023.
52. Siontis KC, Zhang X, Eckard A, Bhave N, Schaubel DE, He K, et al. 64. De Vriese AS, Caluwe R, Bailleul E, De Bacquer D, Borrey D, Van Vlem B,
Outcomes Associated With Apixaban Use in Patients With End-Stage et al. Dose-finding study of rivaroxaban in hemodialysis patients. Am J
Kidney Disease and Atrial Fibrillation in the United States. Circulation. Kidney Dis. 2015;66(1):91-8.
2018;138(15):1519-29.
53. Reinecke H, Engelbertz C, Bauersachs R, Breithardt G, Echterhoff HH,
Gerss J, et al. A Randomized Controlled Trial Comparing Apixaban Konflikt interesa: Nema
With the Vitamin K Antagonist Phenprocoumon in Patients on Chronic
Hemodialysis: The AXADIA-AFNET 8 Study. Circulation. 2023;147(4):296- Primljeno: 05. 11. 2024.
309.
Prihvaćeno: 20. 11. 2024.
54. Pokorney SD, Chertow GM, Al-Khalidi HR, Gallup D, Dignacco P, Onlajn: 31. 12. 2024.
Mussina K, et al. Apixaban for Patients With Atrial Fibrillation on
Hemodialysis: A Multicenter Randomized Controlled Trial. Circulation.
2022;146(23):1735-45.
55. Stanifer JW, Pokorney SD, Chertow GM, Hohnloser SH, Wojdyla DM,
Garonzik S, et al. Apixaban Versus Warfarin in Patients With Atrial
Fibrillation and Advanced Chronic Kidney Disease. Circulation.
2020;141(17):1384-92.

80 DOI: 10.5937/Galmed2412058S